Scarica l'app Stockscreener
6.405
1.10%
0.07
Precedente Chiudi:
$6.335
Aprire:
$6.33
Volume 24 ore:
193.29K
Relative Volume:
0.92
Capitalizzazione di mercato:
$228.45M
Reddito:
$128.45M
Utile/perdita netta:
$6.54M
Rapporto P/E:
128.10
EPS:
0.05
Flusso di cassa netto:
$-8.79M
1 W Prestazione:
+12.07%
1M Prestazione:
-2.21%
6M Prestazione:
+26.58%
1 anno Prestazione:
-1.91%
Intervallo 1D:
$6.25
$6.55
Intervallo di 1 settimana:
$5.62
$6.55
Portata 52W:
$3.6793
$7.99
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Nome
Lifecore Biomedical Inc
Settore
Telefono
(952) 368-4300
Indirizzo
3515 LYMAN BOULEVARD, CHASKA
Confronta LFCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
6.405 | 228.45M | 128.45M | 6.54M | -8.79M | 0.05 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-05 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | Downgrade | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Borsa (LFCR) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Lifecore Appoints Top Legal Executive: Stock Price Targets Set at 5x Current Value - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer - Contract Pharma
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer - GlobeNewswire
Lifecore Strengthens Leadership: Former Viatris Legal Chief Joins to Drive Strategic Growth - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Prudential Financial Inc. Makes New $95,000 Investment in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical secures stockholder nod for share issuance - Investing.com Australia
Lifecore Biomedical secures stockholder nod for share issuance By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out - markets.businessinsider.com
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lifecore Biomedical, Inc. Under Investigation: Schall Law Firm Encourages Investors with Losses to Reach Out - ACCESS Newswire
Hedge funds owners may consider drastic measures as Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) recent US$65m drop adds to long-term losses - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - markets.businessinsider.com
(LFCR) Investment Analysis - news.stocktradersdaily.com
Lifecore Biomedical’s Earnings Call: Strategic Optimism Amid Challenges - MSN
Lifecore Biomedical Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q3 2025 Earnings Call Transcript - Insider Monkey
Sector Update: Health Care Stocks Fall Late Afternoon - MarketScreener
Top Midday Decliners - MarketScreener
Lifecore Biomedical earnings missed by $0.33, revenue topped estimates - Investing.com Canada
Lifecore Biomedical Inc (LFCR) Q3 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Lifecore Biomedical Reports Q3 Fiscal 2025 Results - TipRanks
Lifecore Biomedical (LFCR) Maintains Outlook Amid Strategic Grow - GuruFocus
Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 2027 - MSN
Lifecore Biomedical: Fiscal Q3 Earnings Snapshot - MySA
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results - MarketScreener
Lifecore Biomedical Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Lifecore Biomedical Q3 Swings to Loss, Revenue Lower - MarketScreener
LIFECORE BIOMEDICAL, INC. \DE\ SEC 10-Q Report - TradingView
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update - The Manila Times
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate - Bluefield Daily Telegraph
Lifecore Biomedical Secures Multiple Development Deals Despite Q3 Revenue Dip - Stock Titan
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
LIFECORE BIOMEDICAL Earnings Preview: Recent $LFCR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Charles Schwab Investment Management Inc. Purchases 13,922 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical (LFCR) Projected to Post Quarterly Earnings on Thursday - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bank of New York Mellon Corp Boosts Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025 - GlobeNewswire
Lifecore Biomedical Earnings: Key Q3 Financial Results Coming April 3What to Watch - Stock Titan
Head to Head Comparison: Lifecore Biomedical (NASDAQ:LFCR) & BetterLife Pharma (OTCMKTS:PVOTF) - Defense World
(LFCR) Long Term Investment Analysis - Stock Traders Daily
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Lifecore Biomedical Inc Azioni (LFCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):